Monday, September 15, 2025

Latest

MindMed Reveals Favorable Results From Phase 1 Trial Of Drug Candidate For Opioid Withdrawal Treatment

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results from the phase 1 clinical trial for its opioid withdrawal treatment drug candidate. The drug is said to have shown favorable safety and tolerability among the trial’s subjects.

“As there is a major unmet need to address the ongoing and ever-growing opioid crisis, we are very pleased with the results from our Phase 1 trial, which underscore the potential clinical utility of MM-110 to safely mitigate symptoms of opioid withdrawal,” said Chief Medical Officer Dr. Daniel Karlin.

The phase 1 trial was designed to assess the safety, tolerability, pharmacokinetics, and neurocognitive effects of MM-110 in 108 healthy subjects. The results showed that the drug administration was well-tolerated up to 500mg per day in the single ascending dose and 60 mg per day for seven days in the multiple-ascending dose.

No serious adverse effects were also observed in the trial.

According to the biotech firm, MM-110 is an α3β4 nicotinic cholinergic receptor antagonist and non-hallucinogenic proprietary congener of ibogaine.

The results have been guiding the firm’s upcoming phase 2a trial.

Mind Medicine Inc. last traded at $0.94 on the NEO.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from...

Monday, November 2, 2020, 10:45:02 AM

MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its...

Friday, April 21, 2023, 09:41:30 AM

MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects...

Thursday, May 20, 2021, 08:38:23 AM

Mindmed To Conduct 15-To-1 Reverse Split To Meet Nasdaq Listing Requirements

In a classic Canadian small cap move, Mind Medicine (NEO: MMED) last night announced that...

Friday, August 5, 2022, 08:42:02 AM

Proxy Fight Looms For MindMed Vs. Co-Founder

Mind Medicine’s (NASDAQ: MNMD) filed its preliminary proxy materials on Tuesday with the U.S. Securities and...

Wednesday, April 19, 2023, 09:43:00 AM